Nursing care
Cervical ripening agents: dinoprostone monitoring, insert removal and oxytocin timing
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated October 2026
Short answer
Dinoprostone is a prostaglandin E2 product placed in the vagina or cervix to soften an unfavourable cervix before induction. The nurse monitors contractions and fetal heart rate continuously, removes the insert for tachysystole, fetal heart rate concerns, ruptured membranes or active labour, and follows the label interval before any oxytocin is started.
How prostaglandin ripening prepares the cervix
Dinoprostone is a synthetic prostaglandin E2. It softens, thins and begins to dilate the cervix, and it also makes the uterine muscle more responsive to oxytocin, whether that oxytocin is the body's own or given by infusion. That second effect explains why contractions can start or intensify after placement and why the drug is used only where intrapartum monitoring is available.
Two formulations appear in exam questions. The vaginal insert is a controlled-release pessary on a retrieval tape, so it can be pulled out quickly if problems develop. The endocervical gel is instilled into the cervical canal and cannot be retrieved. The removable insert gives the nurse a fast first action; with gel, the response relies on stopping further doses and escalating.
Contraindications the nurse checks before placement
Labelled contraindications include a prior caesarean birth or major uterine surgery, cephalopelvic disproportion, suspected fetal compromise where birth is not imminent, unexplained vaginal bleeding, and concurrent intravenous oxytocin. The gel label adds placenta praevia, non-vertex presentation and an already hyperactive uterine pattern. A scarred uterus raises rupture risk once strong contractions begin, so it is the classic exam trap.
Caution groups also matter. Prostaglandins can raise intraocular pressure, so a history of glaucoma is reported to the prescriber, and both labels advise care in asthma. The insert label states it should be removed if the membranes rupture because a change in vaginal pH can speed drug release. Before placement, confirm a reassuring baseline fetal heart tracing and document contraction frequency.
Recognising tachysystole and removing the insert
Uterine tachysystole means too many contractions in a set period, which shortens the rest time the placenta needs to reoxygenate the fetus. The insert label directs removal for tachysystole, a hypertonic or sustained contraction, a fetal heart rate concern, rupture of membranes, or the onset of labour. It is also removed at the end of the maximum labelled dwell time even if nothing has happened.
If tachysystole occurs, the nurse pulls the tape to remove the insert, then applies the unit's intrauterine resuscitation steps, such as lateral positioning and fluids, and notifies the prescriber. The label reports that fetal heart changes generally settled after removal. The insert is frozen until use, and the patient stays lying down for a short labelled period after insertion before walking.
Timing oxytocin after ripening
Prostaglandin and oxytocin effects add together, so the two are not run at the same time. The insert label calls for removal at least 30 minutes before oxytocin begins. The gel label suggests a longer interval, measured in hours, before intravenous oxytocin. Exam answers that start oxytocin while an insert is still in place, or immediately after gel, are unsafe.
Rarer serious events named in the labels include amniotic fluid embolism and postpartum disseminated intravascular coagulation, so sudden breathlessness, hypotension, altered consciousness or abnormal bleeding needs emergency escalation. Teaching covers what the patient may feel, the need to report strong continuous pain, leaking fluid or bleeding, and why monitoring continues even when contractions seem mild.
Working a hypothetical ripening scenario
Consider an imagined patient at term with a dinoprostone insert in place for several hours. The monitor now shows contractions coming very close together with recurrent late decelerations. The options are to start the oxytocin ordered for later, reassure her that ripening is working, remove the insert and begin intrauterine resuscitation, or wait for the next cervical check.
Removing the insert is the best first action because it stops the drug source driving excessive contractions and fetal stress. Starting oxytocin would add stimulation, reassurance ignores an abnormal tracing, and a cervical check gives no help to the fetus. After removal, position the patient laterally, follow protocol and notify the provider. This is a study scenario, not a real exam item.
Sources and further reading
DailyMed: Cervidil (dinoprostone) vaginal insert prescribing information. Mechanism, contraindications, removal triggers, 30-minute interval before oxytocin, recumbent period, frozen storage, glaucoma and ruptured membranes cautions.
DailyMed: Prepidil (dinoprostone) endocervical gel prescribing information. Gel contraindications, asthma and glaucoma cautions, monitoring of uterine activity and fetal status, interval before oxytocin, DIC and amniotic fluid embolism warnings.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our maternity and newborn practice questions are the closest set to what this page covers.
Common questions
Why is a dinoprostone insert easier to manage than the gel?
The insert sits on a retrieval tape, so the nurse can remove it within seconds if tachysystole or a fetal heart rate concern develops. Gel placed in the cervical canal cannot be withdrawn.
Can oxytocin run while a dinoprostone insert is in place?
No. Concurrent intravenous oxytocin is a labelled contraindication, and the insert should be out for at least 30 minutes before oxytocin is started, according to the prescriber's plan.
Which history should make the nurse question a prostaglandin ripening order?
A previous caesarean birth or major uterine surgery is the key one, along with unexplained bleeding, cephalopelvic disproportion and an abnormal fetal heart tracing. Glaucoma and asthma warrant caution and a call to the prescriber.